ISR In All Its Radiance, GNCA's Herpes Drug Meets Trial Goal, AMAG On A High

(RTTNews) - AMAG Pharmaceuticals Inc.'s (AMAG) Lumara Health division is partnering with NurseWise, a national nurse triage and health education provider, to facilitate improved patient compliance with Makena therapy.

Makena is the only FDA-approved treatment indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past. Makena is a weekly injection administered by a healthcare provider, starting as early as week 16 of the pregnancy, and given weekly until week 37 or the baby is born, whichever occurs first.

AMAG touched a new high of $68.23 on Wednesday before closing the day's trading at $67.83, up 3.70%.

Alnylam Pharmaceuticals Inc.'s (ALNY) drug candidate Revusiran, currently in phase III development for the treatment of Familial Amyloidotic Cardiomyopathy, has been granted Orphan Drug Designation by the FDA.

ALNY closed Wednesday's trading at $123.95, up 5.64%.

Genocea Biosciences Inc.'s (GNCA) phase II dose optimization trial evaluating GEN-003 for the treatment of genital herpes has demonstrated highly statistically significant 55% reduction in viral shedding rate with best dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant.

GNCA closed Wednesday's trading 8.83% higher at $11.59.

Shares of IsoRay Inc. (ISR) skyrocketed more than 90% on Wednesday, following an on-line publication of the first major peer reviewed study, which revealed improved results of the company's Cesium-131 seeds in the treatment of lung cancer.

Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body.

According to the publication titled "Analysis of Stereotactic Radiation vs. Wedge Resection vs Wedge Resection Plus Cesium-131 Brachytherapy in Early-stage Lung Cancer", Cesium-131 demonstrated 96% success in local control and 100% survival at 5 years in high risk patients.

The study concludes that for high risk wedge resection (a type of lung cancer surgery), the use of Cesim-131 brachytherapy is a better choice.

ISR touched a new high of $3.38 on Wednesday's before closing the day's trading 93.79% higher at $3.12.